MRK - Kitov Pharma: NT-219 Data Reveals Ability To Reverse Pancreatic Cancer Drugs Resistance And The Market Doesn't Care
On September 9th, Kitov Pharma (KTOV) presented proof-of-concept data displaying NT-219’s mechanism of action in reversing cancer drug resistance in pre-clinical models. NT-219 is a “first-in-class small molecule bi-specific inhibitor” of STAT3 and IRS1/2. Previously, Kitov has shown preclinical data that revealed NT-219’s ability to reverse a tumor’s resistance to gemcitabine (Figure 1).
Figure 1: NT-219 Gemcitabine (Source KTOV)
One of these model sets recorded complete response in about half of the group, which is astounding, to say the least. However, NT-219 is not limited to gemcitabine. In fact, the drug